卵巢上皮性癌P53和c-erbB-2的表达及其临床意义  

Significane of expression of P53 and c-erbB-2 in ovarian epithelial carcinoma

作　　者：吴小华 范金兰[1] 于惠敏[1] 宋俊芬[1] 张晖[1] 段惠军[2] 

机构地区：[1]河北医科大学第四医院妇产科,050011 [2]河北医科大学基础医学院病理教研室

出　　处：《河北医药》1999年第5期344-347,共4页Hebei Medical Journal

摘　　要：目的：探讨卵巢上皮性癌（简称卵巢癌）P53和c－erbB-2表达的临床意义。方法：用免疫组织《已学法检测P53和C－CrbB－2，结合临床病理及肿瘤的生物学行为进行分析。结果：P53在高分化卵巢癌中的表达频率显著低于中、低分化癌，P53表达阳性组的卵巢癌对化疗不敏感，其预后亦明显劣于阴性组卵巢癌。卵巢癌的c－erbB－2表达与临床期别、组织学类型和分级、残余瘤大小、化疗疗效和预后均无显著相关性。结论：P53是评价卵巢癌化疗耐药性和预后的可靠指标。Objcctive: To cxplore the clinical significance of P53 and c-erbB-2 expression in ovarian epithelial carcinoma. Metheds: The exprcssion of P53 and c-erbR2 were examined by immunohistochemical method, and the relationship between the expression of two factors and clinicopathologic features, resistance to chcmothcrapy and prognosis were analyzed. Results: The exprcssion P53 had significant lower frequeney in well-differentiated ovarian tumor than mid- and poor-differentiated ovarian tumor. P53 positive tumors related with drug resistance and poor prognosis significantly. The expression of c-crbB-2 was not associated with FlGD stage, histologic type, grade and residual tumor. c-erbB-2 did not appear to be a valuable drug rcsistant factor. Conclusion :P53 expression in ovari-an cancer is related to drug resistance, and it is a useful prognostic factor.

关 键 词：卵巢肿瘤 P53 原癌基因 C-ERBB-2 上皮性癌 

分 类 号：R737.31[医药卫生—肿瘤]